THOUSAND OAKS, Calif., March 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American College of Cardiology (ACC.17) Scientific Sessions on Friday, March 17, 2017, at noon ET. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss Amgen's cardiovascular program and data presented at ACC.17, including the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER) Phase 3 results.
Live audio of the investor meeting will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed from Amgen's website, www.amgen.com, under Investors.
Webcasts of Late-Breaking Clinical Trial Presentations
Detailed results from the Repatha cardiovascular outcomes trial (FOURIER) will be featured as a late-breaking oral presentation at ACC.17 on Friday, March 17 at 9 a.m. ET. A second late-breaking oral presentation, the Repatha cognitive function trial (EBBINGHAUS), will be presented at ACC.17 on Saturday, March 18 at 9 a.m. ET.
Live audio and video of these two late-breaking clinical trial presentations will be webcast over the internet simultaneously with the presentations and will be available to members of the news media, investors and the general public. The webcasts can be accessed from Amgen's website, www.amgen.com, under Investors.
Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar on Amgen's website, www.amgen.com. The webcasts will be archived and available for replay for at least 90 days after the event.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Kristen Neese, 805-313-8267 (media)
Arvind Sood, 805-447-1060 (investors)